INVESTORS

Adagio is developing differentiated antibodies for the prevention and treatment of COVID-19 and potentially emergent coronaviruses. Our portfolio includes multiple, non-competing antibodies with distinct binding targets; our lead monoclonal antibody candidate, ADG20, is currently being evaluated in two late-stage clinical trials.

About Adagio

Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with thirdparty contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.